| Literature DB >> 25962112 |
Rujipat Wasitthankasem1, Sompong Vongpunsawad1, Nipaporn Siripon1, Chutima Suya2, Phrutsada Chulothok2, Kasemporn Chaiear3, Pairaya Rujirojindakul4, Sawan Kanjana5, Apiradee Theamboonlers1, Pisit Tangkijvanich6, Yong Poovorawan1.
Abstract
The majority of hepatitis C virus (HCV) infection results in chronic infection, which can lead to liver cirrhosis and hepatocellular carcinoma. Global burden of hepatitis C virus (HCV) is estimated at 150 million individuals, or 3% of the world's population. The distribution of the seven major genotypes of HCV varies with geographical regions. Since Asia has a high incidence of HCV, we assessed the distribution of HCV genotypes in Thailand and Southeast Asia. From 588 HCV-positive samples obtained throughout Thailand, we characterized the HCV 5' untranslated region, Core, and NS5B regions by nested PCR. Nucleotide sequences obtained from both the Core and NS5B of these isolates were subjected to phylogenetic analysis, and genotypes were assigned using published reference genotypes. Results were compared to the epidemiological data of HCV genotypes identified within Southeast Asian. Among the HCV subtypes characterized in the Thai samples, subtype 3a was the most predominant (36.4%), followed by 1a (19.9%), 1b (12.6%), 3b (9.7%) and 2a (0.5%). While genotype 1 was prevalent throughout Thailand (27-36%), genotype 3 was more common in the south. Genotype 6 (20.9%) constituted subtype 6f (7.8%), 6n (7.7%), 6i (3.4%), 6j and 6m (0.7% each), 6c (0.3%), 6v and 6xa (0.2% each) and its prevalence was significantly lower in southern Thailand compared to the north and northeast (p = 0.027 and p = 0.030, respectively). Within Southeast Asia, high prevalence of genotype 6 occurred in northern countries such as Myanmar, Laos, and Vietnam, while genotype 3 was prevalent in Thailand and Malaysia. Island nations of Singapore, Indonesia and Philippines demonstrated prevalence of genotype 1. This study further provides regional HCV genotype information that may be useful in fostering sound public health policy and tracking future patterns of HCV spread.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25962112 PMCID: PMC4427325 DOI: 10.1371/journal.pone.0126764
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Distribution of HCV genotypes and subtypes in the 4 regions of Thailand.
Pie charts indicate the genotypic distribution in the North, Northeast, Central and South based on the analysis of 588 samples. The genotype or subtype is indicated in a bracket, accompanied by the proportion in percentage.
Characteristics and genotypes of HCV found in Thailand.
| North | Northeast | Central | South | Total | |
|---|---|---|---|---|---|
|
| 82 | 132 | 256 | 118 | 588 |
|
| 40.0 (10.4) | 41.5 (9.4) | 43.6 (11.4) | 37.8 (9.0) | 41.5 (10.6) |
|
| 70/12 | 98/34 | 163/93 | 96/22 | 427/161 |
|
|
|
|
|
|
|
| 1a | 20 (24.4) | 16 (12.1) | 53 (20.7) | 28 (23.7) | 117 (19.9) |
| 1b | 6 (7.3) | 20 (15.2) | 38 (14.8) | 10 (8.5) | 74 (12.6) |
|
|
|
|
|
|
|
| 2a | 1 (1.2) | 0 (0.0) | 2 (0.8) | 0 (0) | 3 (0.5) |
|
|
|
|
|
|
|
| 3a | 19 (23.2) | 52 (39.4) | 98 (38.3) | 45 (38.1) | 214 (36.4) |
| 3b | 13 (15.9) | 9 (6.8) | 18 (7.0) | 17 (14.4) | 57 (9.7) |
|
|
|
|
|
|
|
| 6c | 2 (2.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (0.3) |
| 6f | 7 (8.5) | 15 (11.3) | 21 (8.2) | 3 (2.5) | 46 (7.8) |
| 6i | 1 (1.2) | 12 (9.1) | 7 (2.7) | 0 (0.0) | 20 (3.4) |
| 6j | 0 (0.0) | 0 (0.0) | 4 (1.6) | 0 (0.0) | 4 (0.7) |
| 6m | 4 (4.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 4 (0.7) |
| 6n | 8 (9.8) | 7 (5.3) | 15 (5.9) | 15 (12.7) | 45 (7.7) |
| 6v | 0 (0.0) | 1 (0.8) | 0 (0.0) | 0 (0.0) | 1 (0.2) |
| 6xa | 1 (1.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.2) |
Distribution of HCV genotypes in Southeast Asian countries.
| Country | Year | Sample No. | Sample group | Genotyping method | Genotype number (%) | Reference | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 6 | UN | ||||||
|
| 2001 | 24 | Liver disease | Primer specific PCR | 4(16.7) | 0 | 18(75.0) | 0 | 0 | 2(8.3) | Nakai et al. 2001 [ |
| 2004 | 110 | Blood donor | Phylogentic | 35 (31.8) | 0 | 52(47.3) | 0 | 23(20.9) | 0 | Shinji et al. 2004 [ | |
| 2007 | 145 | Normal population | Phylogentic | 16(11.0) | 1(0.7) | 57(39.3) | 0 | 71(49.0) | 0 | Lwin et al. 2007 [ | |
| 2011 | 15 | Migrant worker | Phylogentic | 2(13.4) | 0 | 9(60) | 0 | 4(26.6) | 0 | Akkarathamrongsin et al. 2011 [ | |
| 2014 | 4 | US-bound refugee | Phylogentic | 0 | 0 | 1(25) | 0 | 3(75) | 0 | Mixson-Hayden et al. 2014 [ | |
|
| 2009 | 16 | Liver disease | Phylogentic | 0 | 0 | 0 | 0 | 16(100) | 0 | Pybus et al. 2009 [ |
| 2011 | 40 | Blood donor | Phylogentic | 2(5.0) | 0 | 0 | 0 | 38(95.0) | 0 | Hubchen et al. 2011 [ | |
|
| 2009 | 70 | Blood donor | Phylogentic | 33(47.1) | 0 | 4(5.7) | 0 | 33(47.1) | 0 | Pham et al. 2009 [ |
| 2010 | 114 | IVDU | Phylogentic | 75(65.8) | 1(0.9) | 10(8.8) | 0 | 28(24.5) | 0 | Tanimoto et al. 2010 [ | |
| 2011 | 842 | Blood donor | Nucleotide BLAST | 256(30.4) | 128(15.2) | 0 | 0 | 458(54.4) | 0 | Pham et al. 2011 [ | |
| 2012 | 277 | High risk groups | Phylogentic | 166(59.9) | 1(0.4) | 5(1.8) | 0 | 105(37.9) | 0 | Dunford et al. 2012 [ | |
| 2014 | 9 | Normal population | Not mentioned | 1(11.1) | 1(11.1) | 1(11.1) | 0 | 6 (66.7) | 0 | Do et al. 2014 [ | |
| 2014 | 236 | Blood donor and Liver disease | Phylogentic | 77(32.6) | 34(14.4) | 0 | 0 | 125(53.0) | 0 | Li et al. 2014 [ | |
|
| 2011 | 25 | Migrant worker | Phylogentic | 6(24.0) | 0 | 5(20.0) | 0 | 14(56.0) | 0 | Akkarathamroongsin et al. 2011 [ |
| 2014 | 11 | Normal population | Not mentioned | 3(27.3) | 0 | 0 | 0 | 6(54.5) | 2(18.2) | Yamada et al. 2014 [ | |
|
| 2007 | 45 | Blood donor | Phylogentic | 16(35.6) | 1(2.2) | 24(53.3) | 0 | 4(8.9) | 0 | Sunanchaikarn et al. 2007 [ |
| 2014 | 588 | Blood donor and Liver disease | Phylogentic | 191(32.5) | 3(0.5) | 271(46.1) | 0 | 123(20.9) | 0 | This study | |
|
| 2012 | 28 | Hemodialysis patient | Phylogentic | 7(25.0) | 0 | 19(67.9) | 1(3.6) | 1(3.6) | 0 | Hairul et al. 2012 [ |
| 2013 | 37 | Liver disease | Nucleotide BLAST | 10(27.0) | 0 | 27(73) | 0 | 0 | 0 | Mohamed et al. 2013 [ | |
| 2014 | 17 | Liver disease | Nucleotide BLAST | 5(29.4) | 0 | 12(70.6) | 0 | 0 | 0 | Mohamed et al. 2014 [ | |
|
| 1995 | 16 | Liver disease | Nucleotide homology | 11(68.8) | 2(12.5) | 2(12.5) | 1(6.2) | 0 | 0 | Ng et al. 1995 [ |
| 1995 | 11 | Not mentioned | Aminoacid similarity | 10(90.9) | 0 | 1(9.1) | 0 | 0 | 0 | Greene et al. 1995 [ | |
|
| 2000 | 57 | Blood donor | Primer specific PCR | 39(60.9) | 12(18.8) | 8(12.5) | 0 | 0 | 5(7.8) | Inoue et al. 2000 [ |
| 2008 | 104 | Blood donor and liver disease | Phylogentic | 64(61.5) | 21(20.2) | 18(17.3) | 1(1.0) | 0 | 0 | Utama et al. 2008 [ | |
| 2010 | 150 | Liver disease | Phylogentic | 109(72.7) | 24(16.0) | 17(11.3) | 0 | 0 | 0 | Utama et al 2010 [ | |
| 2012 | 44 | HIV patient | Phylogentic | 28(63.6) | 0 | 12(27.3) | 3(6.8) | 1(2.3) | 0 | Anggorowati et al. 2012 [ | |
| 2013 | 30 | Prisoner | Phylogentic | 20(66.7) | 0 | 8(26.6) | 2(6.7) | 0 | 0 | Prasetyo et al. 2013 [ | |
| 2014 | 99 | HIV patient | Nucleotide sequence homology | 57(57.6) | 2(2.0) | 39(39.4) | 1(1.0) | 0 | 0 | Juniastuti et al. 2014 [ | |
|
| 2005 | 23 | IVDU | Phylogentic | 15(65.2) | 8(34.8) | 0 | 0 | 0 | 0 | Agdamag et al. 2005 [ |
| 2009 | 444 | IVDU and dialysis patient | Phylogentic | 325(73.2) | 117(26.4) | 0 | 1(0.2) | 1(0.2) | 0 | Kageyama et al. 2009 [ | |
The number of samples examined for each study with assignable HCV genotype was included.
aIntravenous drug user, commercial sex worker, dialysis worker and multi-transfused patient.
Fig 2Distribution of HCV genotypes in Southeast Asian region compiled from published literatures.
Pie charts indicate the genotypic distribution found in each country. The genotype or subtype is indicated in a bracket, accompanied by the proportion in percentage [11–13, 17–20].